Melarsoprol Resistance in African Trypanosomiasis

Area of Science:

• Parasitology
• Molecular Biology
• Drug Resistance Studies

Background:

• Arsenicals, like melarsoprol, have been used for over a century to treat human African trypanosomiasis (sleeping sickness).
• Despite their effectiveness, toxicity and the emergence of drug-resistant parasites have been significant challenges.
• Parasite resistance to melarsoprol emerged in the 1970s and became widespread by the late 1990s.

Purpose of the Study:

• To investigate the genetic basis of melarsoprol resistance in human African trypanosomiasis.
• To understand the role of parasite solute transporters in drug resistance mechanisms.

Main Methods:

• Genetic analysis of melarsoprol-resistant trypanosome strains.
• Identification of mutations in parasite solute and drug transporters.

Main Results:

• Widespread melarsoprol resistance is attributed to mutations in aquaglyceroporin 2 (AQP2), a key parasite transporter.
• This is the first identified genetic basis for widespread drug resistance in trypanosomiasis.
• The study demonstrates a direct link between melarsoprol and AQP2 function.

Conclusions:

• Mutations in the AQP2 transporter are responsible for widespread melarsoprol resistance in sleeping sickness.
• Drug transporters can enhance drug selectivity but also pose a risk for resistance development.
• Understanding these mechanisms is crucial for developing durable and effective treatments for trypanosomiasis.